Adipothera
Adipothera develops therapies that repair damaged tissue rather than manage symptoms. We target the stromal microenvironment to address the underlying biology of fibrosis and tissue remodeling. Our lead program addresses radiation-induced skin injury across both medical countermeasure and oncology supportive care settings, with an expanding pipeline in lymphedema and pathological bone formation.
Industries
N/A
Nr. of Employees
small (1-50)
Adipothera is currently seeking investment
Adipothera is seeking a seed investment in the range of 1m-5m
Products
AT-001 (Topical)
A topical drug candidate that drives stromal reprogramming to restore normal tissue architecture in radiation-induced skin injury and lymphedema.
AT-002 (Oral)
An oral drug candidate designed to prevent and interrupt pathological bone formation, with applications in trauma-associated heterotopic ossification and fibrodysplasia ossificans progressiva.
AT-001 (Topical)
A topical drug candidate that drives stromal reprogramming to restore normal tissue architecture in radiation-induced skin injury and lymphedema.
AT-002 (Oral)
An oral drug candidate designed to prevent and interrupt pathological bone formation, with applications in trauma-associated heterotopic ossification and fibrodysplasia ossificans progressiva.
Expertise Areas
- Stromal reprogramming therapeutics
- Radiation injury and radiodermatitis
- Heterotopic ossification prevention
- 505(b)(2) drug repurposing
Key Technologies
- Transcriptomic drug repurposing
- Topical and local drug delivery
- Radiation injury and HO preclinical models
- 505(b)(2) regulatory strategy
Key People
Chief Executive Officer and Founder
Founder and Board Member
Chief Executive Officer and Founder
Founder and Board Member
News & Updates
Core technology for programming stromal responses is validated, enabling new classes of drug targets.
Progress in advanced preclinical studies guides further development and dose selection for the oral candidate.
Submission of preclinical results for the AT-002 program to a high-impact translational journal.
Intellectual property filings covering proprietary chemical series that underpin the company's lead candidates.
Core technology for programming stromal responses is validated, enabling new classes of drug targets.
Progress in advanced preclinical studies guides further development and dose selection for the oral candidate.
Submission of preclinical results for the AT-002 program to a high-impact translational journal.
Intellectual property filings covering proprietary chemical series that underpin the company's lead candidates.